However, in the DESTINY-Breast03 trial, T-Dxd did not show a significant improvement in PFS compared to T-DM1 for previously treated HER2-positive MBC patients receiving trastuzumab and paclitaxel analogs, although it did result in a notable increase in mPFS for patients with HER2-positive breast cancer (83). Here, ERBB2 is linked to breast carcinoma.